Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17929
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurvenich, Ingrid J G-
dc.contributor.authorParakh, Sagun-
dc.contributor.authorParslow, Adam C-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorGan, Hui K-
dc.contributor.authorScott, Andrew M-
dc.date2018-03-08-
dc.date.accessioned2018-06-21T05:31:11Z-
dc.date.available2018-06-21T05:31:11Z-
dc.date.issued2018-03-08-
dc.identifier.citationThe AAPS journal 2018; 20(2): 43-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17929-
dc.description.abstractThe selection of therapeutic dose for the most effective treatment of tumours is an intricate interplay of factors. Molecular imaging with positron emission tomography (PET) or single-photon emission computed tomography (SPECT) can address questions central to this selection: Does the drug reach its target? Does the drug engage with the target of interest? Is the drug dose sufficient to elicit the desired pharmacological effect? Does the dose saturate available target sites? Combining functional PET and SPECT imaging with anatomical imaging technologies such as magnetic resonance imaging (MRI) or computed tomography (CT) allows drug occupancy at the target to be related directly to anatomical or physiological changes in a tissue resulting from therapy. In vivo competition studies, using a tracer amount of radioligand that binds to the tumour receptor with high specificity, enable direct assessment of the relationship between drug plasma concentration and target occupancy. Including imaging studies in early drug development can aid with dose selection and suggest improvements for patient stratification to obtain higher effective utility from a drug after approval. In this review, the potential value of including translational receptor occupancy studies and molecular imaging strategies early on in drug development is addressed.-
dc.language.isoeng-
dc.subjectdrug development-
dc.subjectpositron emission tomography (PET)-
dc.subjectreceptor imaging-
dc.subjectreceptor occupancy-
dc.subjectsingle–photon emission tomography (SPECT)-
dc.titleReceptor Occupancy Imaging Studies in Oncology Drug Development.-
dc.typeJournal Article-
dc.identifier.journaltitleThe AAPS journal-
dc.identifier.affiliationTumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Melbourne, Australia-
dc.identifier.doi10.1208/s12248-018-0203-z-
dc.identifier.orcid0000-0001-8641-456X-
dc.identifier.orcid0000-0002-6656-295X-
dc.identifier.pubmedid29520671-
dc.type.austinJournal Article-
local.name.researcherGan, Hui K
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.